A detailed history of Wolverine Trading, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 28,271 shares of ALT stock, worth $227,581. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,271
Previous 27,434 3.05%
Holding current value
$227,581
Previous $182,000 4.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $4,603 - $6,779
837 Added 3.05%
28,271 $173,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $26,565 - $45,983
-4,495 Reduced 14.08%
27,434 $182,000
Q1 2024

May 15, 2024

SELL
$8.22 - $13.81 $258,338 - $434,020
-31,428 Reduced 49.6%
31,929 $325,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $135,583 - $736,208
63,357 New
63,357 $712,000
Q2 2023

Aug 23, 2023

BUY
$3.45 - $5.97 $36,407 - $63,001
10,553 New
10,553 $37,000
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $150,286 - $315,644
14,085 Added 58.34%
38,227 $482,000
Q2 2022

Aug 15, 2022

BUY
$3.94 - $11.77 $95,119 - $284,151
24,142 New
24,142 $284,000
Q1 2022

May 16, 2022

SELL
$5.9 - $9.45 $197,974 - $317,094
-33,555 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $146,209 - $209,976
16,825 Added 100.57%
33,555 $300,000
Q3 2021

Nov 12, 2021

BUY
$8.43 - $16.81 $43,473 - $86,689
5,157 Added 44.56%
16,730 $213,000
Q2 2021

Aug 06, 2021

SELL
$9.85 - $16.46 $6,432 - $10,748
-653 Reduced 5.34%
11,573 $184,000
Q1 2021

May 14, 2021

SELL
$12.71 - $24.31 $171,330 - $327,698
-13,480 Reduced 52.44%
12,226 $166,000
Q4 2020

Feb 12, 2021

BUY
$7.84 - $14.22 $201,535 - $365,539
25,706 New
25,706 $290,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.